Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura
Open Access
- 1 May 1997
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 89 (9) , 3097-3103
- https://doi.org/10.1182/blood.v89.9.3097
Abstract
In patients with thrombotic thrombocytopenic purpura (TTP), excessive intravascular platelet aggregation has been associated with appearance in plasma of unusually large von Willebrand factor (vWF ) multimers. These extremely adhesive vWF multimers may arise due to deficiency of a “depolymerase” cleaving vWF to smaller molecular forms, either by reducing the interdimeric disulfide bridges or by proteolytic degradation. We studied the activity of a recently described vWF-cleaving protease in four patients with chronic relapsing TTP. Diluted plasma samples of TTP patients were incubated with purified normal human vWF in the presence of a serine protease inhibitor, at low ionic strength, and in the presence of urea and barium ions. The extent of vWF degradation was assayed by electrophoresis in sodium dodecyl sulfate-agarose gels and immunoblotting. Four patients, that included two brothers, with chronic relapsing TTP displayed either substantially reduced levels or a complete absence of vWF-cleaving protease activity. In none of these patient plasmas was an inhibitor of or an antibody against the vWF-cleaving protease established. Our data suggest that the unusually large vWF multimers found in TTP patients may be caused by deficient vWF-cleaving protease activity. Deficiency of this protease may be inherited in an autosomal recessive manner and seems to predispose to chronic relapsing TTP. The assay of the vWF-cleaving protease activity may be used as a sensitive diagnostic tool for identification of subjects with a latent TTP tendency.Keywords
This publication has 26 references indexed in Scilit:
- Haemolytic-uraemic syndrome: basic scienceThe Lancet, 1994
- Abnormalities of von willebrand factor multimers in drug‐associated thrombotic microangiopathiesAmerican Journal of Hematology, 1993
- Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.Journal of Clinical Investigation, 1991
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991
- Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric sizeBritish Journal of Haematology, 1989
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.Journal of Clinical Investigation, 1986
- Inducible secretion of large, biologically potent von Willebrand factor multimersCell, 1986
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982
- Treatment of Thrombotic Thrombocytopenic Purpura with PlasmaNew England Journal of Medicine, 1977
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970